Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Turnover Ratios
Average No. Days
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
Operational efficiency exhibited a period of gradual decline between 2014 and 2017, followed by a significant improvement in performance metrics during 2018. The most notable shift occurred in the management of working capital and inventory, which led to a drastic reduction in the time required to convert resources into cash.
- Inventory and Receivables Management
- Inventory turnover experienced a downward trend from 0.98 in 2014 to 0.85 in 2017, resulting in the average inventory processing period peaking at 428 days. However, 2018 marked a sharp reversal, with turnover increasing to 1.28 and the processing period dropping to 285 days. Receivables management remained relatively stable throughout the period, with the collection period fluctuating minimally between 49 and 57 days, though a peak in turnover (7.39) and a minimum in collection days (49) were observed in 2018.
- Payables and Credit Utilization
- A consistent trend of extending payment terms is observed. Payables turnover declined steadily from 1.95 in 2014 to 1.40 in 2018. Correspondingly, the average payables payment period grew from 187 days to 260 days, indicating a strategic shift toward utilizing supplier credit to finance operations over a longer duration.
- Operating and Cash Conversion Cycles
- The operating cycle expanded from 428 days in 2014 to a peak of 482 days in 2017, primarily driven by slowing inventory movement. This trend reversed sharply in 2018, with the operating cycle contracting to 334 days. The cash conversion cycle remained elevated between 233 and 262 days for most of the period but saw a substantial reduction to 74 days in 2018. This improvement was the result of both accelerated inventory processing and the extension of payables payment periods.
- Working Capital Efficiency
- Working capital turnover remained low and relatively stagnant between 1.00 and 1.41 from 2014 to 2017. A significant spike to 3.05 occurred in 2018, signaling a substantial increase in the efficiency with which working capital was utilized to generate revenue.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Inventory Turnover
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cost of goods sold, excluding amortization of acquired intangible assets | 587) | 461) | 438) | 420) | 386) | |
| Inventory | 458) | 541) | 498) | 443) | 393) | |
| Short-term Activity Ratio | ||||||
| Inventory turnover1 | 1.28 | 0.85 | 0.88 | 0.95 | 0.98 | |
| Benchmarks | ||||||
| Inventory Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
Inventory turnover = Cost of goods sold, excluding amortization of acquired intangible assets ÷ Inventory
= 587 ÷ 458 = 1.28
2 Click competitor name to see calculations.
Between 2014 and 2018, the company experienced a distinct shift in its inventory management efficiency, characterized by a multi-year period of declining turnover followed by a significant recovery in the final year.
- Cost of Goods Sold (COGS)
- A consistent upward trajectory is observed in the cost of goods sold, excluding amortization of acquired intangible assets. The expenditure grew steadily from 386 million US$ in 2014 to 461 million US$ in 2017, followed by a sharp acceleration in 2018, where it reached 587 million US$.
- Inventory Valuation
- Inventory levels exhibited a period of sustained growth from 2014 through 2017, rising from 393 million US$ to a peak of 541 million US$. This growth trend reversed in 2018, with inventory holdings decreasing to 458 million US$.
- Inventory Turnover Ratio
- The inventory turnover ratio showed a progressive decline from 0.98 in 2014 to 0.85 in 2017, suggesting that the growth in inventory holdings outpaced the growth in cost of goods sold during this timeframe. However, the ratio increased substantially to 1.28 in 2018. This reversal indicates a marked improvement in operating efficiency, resulting from the combined effect of higher cost of goods sold and a strategic reduction in total inventory levels.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Receivables Turnover
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net product sales | 15,265) | 12,973) | 11,185) | 9,161) | 7,564) | |
| Accounts receivable, net of allowances | 2,066) | 1,921) | 1,621) | 1,421) | 1,167) | |
| Short-term Activity Ratio | ||||||
| Receivables turnover1 | 7.39 | 6.75 | 6.90 | 6.45 | 6.48 | |
| Benchmarks | ||||||
| Receivables Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
Receivables turnover = Net product sales ÷ Accounts receivable, net of allowances
= 15,265 ÷ 2,066 = 7.39
2 Click competitor name to see calculations.
Net product sales exhibited consistent and significant growth from 2014 to 2018, increasing from 7,564 million USD to 15,265 million USD. Parallel to this revenue expansion, accounts receivable, net of allowances, rose from 1,167 million USD to 2,066 million USD. The proportional increase in receivables relative to sales indicates a stable credit extension strategy during this period of rapid growth.
- Receivables Turnover Trends
- The receivables turnover ratio remained relatively stable between 2014 and 2017, fluctuating slightly between a low of 6.45 and a high of 6.90. A more pronounced increase was observed in 2018, with the ratio reaching 7.39, the highest point in the analyzed period.
- Operational Efficiency Insights
- The stability and subsequent rise in the turnover ratio suggest that the efficiency of credit and collection processes kept pace with the increasing volume of sales. The peak in 2018 indicates an acceleration in the conversion of accounts receivable into cash, reflecting improved liquidity management and more effective collection of outstanding invoices.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Payables Turnover
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cost of goods sold, excluding amortization of acquired intangible assets | 587) | 461) | 438) | 420) | 386) | |
| Accounts payable | 418) | 305) | 247) | 241) | 198) | |
| Short-term Activity Ratio | ||||||
| Payables turnover1 | 1.40 | 1.51 | 1.77 | 1.74 | 1.95 | |
| Benchmarks | ||||||
| Payables Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
Payables turnover = Cost of goods sold, excluding amortization of acquired intangible assets ÷ Accounts payable
= 587 ÷ 418 = 1.40
2 Click competitor name to see calculations.
An analysis of short-term operating activity reveals a consistent expansion in both the cost of goods sold and the balance of accounts payable between 2014 and 2018. While operational costs increased, the growth in payables occurred at a faster relative pace, resulting in a contraction of the payables turnover ratio.
- Cost of Goods Sold Trends
- The cost of goods sold, excluding amortization of acquired intangible assets, grew steadily from $386 million in 2014 to $587 million in 2018. This upward trajectory reflects a consistent increase in the direct costs associated with the company's product offerings over the five-year period.
- Accounts Payable Growth
- Accounts payable experienced significant growth, rising from $198 million in 2014 to $418 million in 2018. The increase in these liabilities outpaced the growth in the cost of goods sold, indicating a larger volume of unpaid supplier obligations at the end of each fiscal year.
- Payables Turnover Analysis
- The payables turnover ratio exhibited a general downward trend, moving from 1.95 in 2014 to 1.40 in 2018. This decline signifies that the company is taking longer to settle its obligations with suppliers. Such a pattern suggests an extension of the payment cycle, which may indicate improved credit terms negotiated with vendors or a strategic effort to optimize working capital by delaying cash outflows.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Working Capital Turnover
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current assets | 9,067) | 14,892) | 10,868) | 9,401) | 9,713) | |
| Less: Current liabilities | 4,057) | 2,987) | 2,959) | 1,969) | 2,112) | |
| Working capital | 5,010) | 11,905) | 7,908) | 7,432) | 7,600) | |
| Net product sales | 15,265) | 12,973) | 11,185) | 9,161) | 7,564) | |
| Short-term Activity Ratio | ||||||
| Working capital turnover1 | 3.05 | 1.09 | 1.41 | 1.23 | 1.00 | |
| Benchmarks | ||||||
| Working Capital Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
Working capital turnover = Net product sales ÷ Working capital
= 15,265 ÷ 5,010 = 3.05
2 Click competitor name to see calculations.
The operational efficiency regarding the utilization of working capital exhibited significant volatility between 2014 and 2018, despite a consistent upward trajectory in net product sales. While revenue grew steadily each year, the working capital base fluctuated, leading to non-linear shifts in the turnover ratio.
- Net Product Sales Performance
- A sustained growth trend is observed in net product sales, which rose from 7,564 million US dollars in 2014 to 15,265 million US dollars by 2018. This consistent increase indicates a steady expansion in revenue generation over the five-year period.
- Working Capital Fluctuations
- Working capital remained relatively stable from 2014 to 2016, followed by a substantial increase to 11,905 million US dollars in 2017. This peak was succeeded by a sharp contraction in 2018, with the value dropping to 5,010 million US dollars, the lowest level recorded in the period.
- Working Capital Turnover Analysis
- The turnover ratio demonstrated an initial improvement from 1.00 in 2014 to 1.41 in 2016, suggesting increasing efficiency in using short-term assets to generate sales. A decline to 1.09 occurred in 2017, coinciding with the surge in working capital. The period concluded with a significant spike to 3.05 in 2018, driven by the combination of peak sales volume and a minimized working capital base, indicating a heightened capacity to generate revenue relative to the investment in operating liquidity.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Average Inventory Processing Period
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Inventory turnover | 1.28 | 0.85 | 0.88 | 0.95 | 0.98 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average inventory processing period1 | 285 | 428 | 415 | 385 | 372 | |
| Benchmarks (no. days) | ||||||
| Average Inventory Processing Period, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 1.28 = 285
2 Click competitor name to see calculations.
Between 2014 and 2018, the efficiency of inventory management exhibited two distinct phases: a period of gradual decline in turnover efficiency followed by a sharp operational improvement in the final year.
- Inventory Turnover Trends
- A consistent downward trend is observed from 2014 to 2017, with the turnover ratio declining from 0.98 to 0.85. This decline indicates a slowing rate of inventory replacement over that four-year span. However, a significant reversal occurred in 2018, where the ratio increased to 1.28, marking the highest turnover rate in the analyzed period.
- Average Inventory Processing Period
- The duration required to process inventory increased steadily from 372 days in 2014 to a peak of 428 days in 2017. This upward trajectory suggests a lengthening of the operating cycle and reduced liquidity of inventory assets. In 2018, a substantial reduction was recorded, with the processing period falling to 285 days, representing a decrease of 143 days compared to the previous year.
- Operational Correlation
- A strong inverse correlation is evident between the turnover ratios and the processing period. The peak in processing duration in 2017 coincides with the lowest turnover ratio, while the marked improvement in 2018 aligns with the highest turnover efficiency. This suggests a significant optimization of short-term operating activity or a shift in inventory management strategy during the final year of the sequence.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Average Receivable Collection Period
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Receivables turnover | 7.39 | 6.75 | 6.90 | 6.45 | 6.48 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average receivable collection period1 | 49 | 54 | 53 | 57 | 56 | |
| Benchmarks (no. days) | ||||||
| Average Receivable Collection Period, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 7.39 = 49
2 Click competitor name to see calculations.
An analysis of the operating activity ratios between 2014 and 2018 indicates a general improvement in the efficiency of credit management and receivables collection. A positive correlation is observed between an increasing turnover ratio and a decreasing collection period, suggesting an optimization of working capital throughout the five-year period.
- Receivables Turnover
- The turnover ratio remained relatively stable in the initial period, moving from 6.48 in 2014 to 6.45 in 2015. An upward trend followed, with the ratio rising to 6.90 in 2016, despite a marginal correction to 6.75 in 2017. The period concluded with a notable increase to 7.39 in 2018, marking the highest level of turnover efficiency in the observed timeframe.
- Average Receivable Collection Period
- The collection period exhibited a corresponding inverse movement to the turnover ratio. After a slight increase from 56 days in 2014 to 57 days in 2015, the period decreased to 53 days in 2016. Following a minor fluctuation to 54 days in 2017, the collection period reached its lowest point of 49 days in 2018. This downward trend reflects an acceleration in the conversion of accounts receivable into liquid assets.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Operating Cycle
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | 285 | 428 | 415 | 385 | 372 | |
| Average receivable collection period | 49 | 54 | 53 | 57 | 56 | |
| Short-term Activity Ratio | ||||||
| Operating cycle1 | 334 | 482 | 468 | 442 | 428 | |
| Benchmarks | ||||||
| Operating Cycle, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 285 + 49 = 334
2 Click competitor name to see calculations.
The operating cycle exhibited a steady expansion from 2014 through 2017, followed by a significant contraction in 2018. This overall trend was primarily driven by fluctuations in inventory management, while the receivable collection process remained relatively stable throughout the analyzed period.
- Average Inventory Processing Period
- A consistent upward trend was observed from 2014 to 2017, with the period increasing from 372 days to a peak of 428 days. This suggests a slowing of inventory turnover during this timeframe. However, a sharp reversal occurred in 2018, where the period decreased substantially to 285 days, indicating a significant improvement in inventory efficiency or a strategic shift in inventory levels.
- Average Receivable Collection Period
- The collection period demonstrated high stability, fluctuating within a narrow range between 49 and 57 days. A slight downward trend is noted toward the end of the period, reaching a five-year low of 49 days in 2018. This indicates a consistent and effective approach to credit management and cash recovery from customers.
- Operating Cycle
- The total operating cycle mirrored the movement of the inventory processing period, rising from 428 days in 2014 to a maximum of 482 days in 2017. The cycle then contracted sharply to 334 days in 2018. Because the receivable collection period remained steady, the overall volatility of the operating cycle is attributed almost entirely to the changes in the time required to process inventory.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Average Payables Payment Period
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Payables turnover | 1.40 | 1.51 | 1.77 | 1.74 | 1.95 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average payables payment period1 | 260 | 241 | 206 | 209 | 187 | |
| Benchmarks (no. days) | ||||||
| Average Payables Payment Period, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 1.40 = 260
2 Click competitor name to see calculations.
An analysis of short-term operating activity indicates a persistent increase in the duration of the payables cycle from 2014 through 2018. The observed trends demonstrate a clear inverse correlation between the payables turnover ratio and the average payment period, reflecting a consistent shift toward the slower settlement of obligations to suppliers.
- Payables Turnover
- A steady downward trend is observed in the payables turnover ratio, which declined from 1.95 in 2014 to 1.40 in 2018. This reduction indicates that the frequency with which the company clears its accounts payable has diminished, signifying a slowing of the payment cycle over the five-year period.
- Average Payables Payment Period
- The average payables payment period expanded significantly, rising from 187 days in 2014 to 260 days in 2018. While the period remained relatively stable between 2015 and 2016, shifting only from 209 to 206 days, it accelerated sharply in the final two years. This substantial extension of payment terms suggests a heightened utilization of supplier credit to manage working capital.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Cash Conversion Cycle
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | 285 | 428 | 415 | 385 | 372 | |
| Average receivable collection period | 49 | 54 | 53 | 57 | 56 | |
| Average payables payment period | 260 | 241 | 206 | 209 | 187 | |
| Short-term Activity Ratio | ||||||
| Cash conversion cycle1 | 74 | 241 | 262 | 233 | 241 | |
| Benchmarks | ||||||
| Cash Conversion Cycle, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 285 + 49 – 260 = 74
2 Click competitor name to see calculations.
The cash conversion cycle exhibited relative stability between 2014 and 2017, fluctuating within a range of 233 to 262 days. However, a significant contraction occurred in 2018, where the cycle dropped sharply to 74 days. This dramatic improvement in liquidity efficiency is primarily attributable to a substantial reduction in inventory holding times coupled with an extended period for settling obligations to suppliers.
- Average Inventory Processing Period
- A gradual upward trend was observed from 2014 to 2017, with the period increasing from 372 days to 428 days, suggesting a slowing of inventory turnover. This trend reversed abruptly in 2018, falling to 285 days, which indicates a marked increase in the efficiency of inventory management or a strategic shift in product turnover.
- Average Receivable Collection Period
- The collection period remained consistently stable throughout the analyzed timeframe, moving from 56 days in 2014 to 49 days in 2018. This stability indicates a disciplined and consistent approach to credit management and a steady rate of cash inflow from customers.
- Average Payables Payment Period
- There was a sustained increase in the time taken to pay suppliers, rising from 187 days in 2014 to 260 days in 2018. This trend suggests an intentional strategy to leverage trade credit, thereby preserving cash reserves and shifting the financing burden to suppliers.
The overall reduction in the cash conversion cycle in 2018 represents a significant optimization of working capital. The convergence of a shorter inventory cycle and a longer payables cycle effectively minimized the gap between cash outflows for production and cash inflows from sales, resulting in a more liquid operational position.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?